SAN DIEGO, Nov. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that President and CEO Theodore Schroeder will present a corporate overview on Friday, December 1, 2006 at 2:30pm Eastern Time (11:30am Pacific Time) during the Piper Jaffray Health Care Conference at the Pierre Hotel in New York City. Mr. Schroeder’s presentation will provide an overview of the company’s two Phase III products in development, including IV APAP for the treatment of acute pain and fever, and Omigard(TM) for the prevention of local catheter site infections.
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceutical’s website at www.cadencepharm.com. To access the presentation, click on the Investor Relations tab and then click on the link entitled “Events and Presentations” on the left side of the screen. The webcast will be available for 30 days and then archived.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. Cadence identifies clinically validated, low-risk late- or commercial-stage compounds that provide near-term opportunities to address the concentrated hospital marketplace. The company currently has two Phase III products in development, including IV APAP, an injectable acetaminophen for the treatment of acute pain and fever, and the topical antimicrobial Omigard(TM) (omiganan) for the prevention of catheter-related infections. For more information about Cadence’s pipeline, visit www.cadencepharm.com.
Forward-Looking Statements
Cadence cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence’s business including, without limitation, the progress and timing of the company’s ongoing and planned clinical trials, difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products and other risks detailed in Cadence’s prior press releases as well as in Cadence’s public filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Contacts: William R. LaRue SVP & Chief Financial Officer Cadence Pharmaceuticals, Inc. 858-436-1400 Susan Neath Media & Investor Relations Porter Novelli Life Sciences 858-527-3486
Cadence Pharmaceuticals, Inc.
CONTACT: William R. LaRue, SVP & Chief Financial Officer of CadencePharmaceuticals, Inc., +1-858-436-1400; or Media & Investor Relations,Susan Neath of Porter Novelli Life Sciences, +1-858-527-3486, for CadencePharmaceuticals, Inc.
Web site: http://www.cadencepharm.com/
